Image from Google Jackets

Biosimilars for Cancer Treatment A Promising Approach

By: Contributor(s): Material type: TextTextLanguage: English Series: https://doi.org/10.1007/978-981-97-3001-8Publication details: Pune, Maharashtra, India : Springer Nature Singapore Pte Ltd : 2024Description: 316 Pages Includes References and IndexISBN:
  • 978-981-97-3000-1
  • 978-981-97-3001-8
Subject(s): Online resources: Summary: The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers. It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments. This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment.
Item type: E-BOOKS
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Status Barcode
E-BOOKS MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO Not for loan 20240822134331.0
Total holds: 0

The book delves into the role of biosimilars in the field of cancer treatment. It also discusses the application of biosimilars in various cancer types, from colorectal and cervical to prostate, gastric, lung, pancreatic, breast, hepatocellular, ovarian, and blood cancers. It contains chapters that focus on the clinical trials of biosimilars, providing insights into the latest research and developments. This book serves as a valuable resource for clinicians, researchers, and anyone seeking a comprehensive understanding of the intersection between biosimilars and cancer treatment.

There are no comments on this title.

to post a comment.
Share
Catholic University of  Health and Allied Sciences - CUHAS
Directorate of ICT @ 2024